Drug Provocation Testing in Brugada Syndrome: A Test of Uncertain Significance

JACC Clin Electrophysiol. 2019 Apr;5(4):513-515. doi: 10.1016/j.jacep.2019.03.003.

Author

Affiliation

¹ Section of Cardiac Electrophysiology, Division of Cardiovascular Diseases, Duke University Medical Center, Durham, North Carolina; Section of Cardiac Electrophysiology, Division of Cardiovascular Diseases, Durham Veterans Affairs Medical Center, Durham, North Carolina. Electronic address: [email protected].

PMID: 31000107
DOI: 10.1016/j.jacep.2019.03.003

No abstract available

Keywords: Brugada syndrome; electrocardiology; sodium channel blocker.

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Ajmaline*
Anti-Arrhythmia Agents
Brugada Syndrome*
Humans
NAV1.5 Voltage-Gated Sodium Channel
Procainamide

Substances

Anti-Arrhythmia Agents
NAV1.5 Voltage-Gated Sodium Channel
Ajmaline
Procainamide